secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-11-28T23:59:59+00:00
Accession:  0001213900-25-115921
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio enters new employment agreements with CEO, CFO, and CSO
------------------------------------------------------------------

- CEO David Moss: $500,000 base salary, 50% bonus target, option for 800,000 shares.
- CFO Cory Ellspermann: $275,000 base salary, 40% bonus target, option for 300,000 shares.
- CSO Mark Lowdell: £300,000 base salary, up to 20% annual bonus, 18-month severance.
- Severance for Moss/Ellspermann: 18 months base salary, prorated bonus, and COBRA payments.
- New agreements effective November 1, 2025; all include change-of-control equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025115921/0001213900-25-115921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025115921/ea0267546-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-115921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer